Introduction: Riociguat treatment has shown beneficial effects in patients with pulmonary arterial hypertension (PAH) in a randomized, placebo-controlled Phase III trial (PATENT-1) and its open-label long-term extension (PATENT-2). Here we investigated the safety and efficacy of riociguat in the subgroup of patients with persistent or recurrent PAH following complete surgical repair of congenital heart disease (CHD) in PATENT-1 and PATENT-2.
Methods: In PATENT-1, treatment-naïve or pretreated patients with PAH received either placebo, riociguat up to 2.5 mg three-times daily (tid) (2.5 mg-maximum group), or riociguat up to 1.5 mg tid (1.5 mg-maximum group; exploratory) for 12 weeks. Patients completing PATENT-1 without ongoing drug-related serious adverse events (SAEs) were eligible to enter PATENT-2, in which all patients received open-label treatment with riociguat.
Results: There were 35 patients with persistent or recurrent PAH after complete surgical repair of CHD in PATENT-1, of whom 33 (94%) entered PATENT-2. At PATENT-1 baseline, 57% of patients with PAH-CHD were treatment-naïve, most had atrial or ventricular septal defects (40% and 34%, respectively), all were in WHO FC II or III (60% and 40%, respectively), and mean time since last corrective surgery was 16.8 years. At Week 12 of PATENT-1, patients in the riociguat 2.5 mgmaximum group showed greater improvements from baseline in 6MWD (primary endpoint) and a range of secondary efficacy endpoints compared with patients receiving placebo (Table 1) . Improvements in efficacy endpoints were also seen in the riociguat 1.5 mg-maximum group. Four (11%) patients reported SAEs during PATENT-1; none were considered drug-related. One patient died owing to right ventricular failure and worsening PAH (riociguat 1.5 mg-maximum group; not considered drug-related) and two patients discontinued treatment; one owing to supraventricular tachycardia and hypotension (riociguat 2.5 mg-maximum group; considered drug-related) and one owing to pneumothorax (placebo group; not considered drug-related). In the PATENT-2 open-label extension (median treatment duration 139 weeks), the improvements in 6MWD and WHO FC observed in PATENT-1 persisted for up to 2 years.
Conclusions: In PATENT-1 and PATENT-2, riociguat improved a range of clinical outcomes in patients with persistent or recurrent PAH after complete surgical repair of CHD. 
